Daniel Rader
Has grant
Chair
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Open
Toward molecular understanding of novel genes and pathways linking lipid metabolism and cardiovascular diseases
Open Date: 2024-01-01
Close Date: 2028-12-31
Articles (24)
Year:
2026
Year:
2026
Year:
2026
Year:
2026
The Genome Informed Risk Assessment (GIRA) report from eMERGE has become a standard approach to implement genomic precision medicine at scale. Here, we assess GIRA's utility and impact in a health care system independent of eMERGE, focusing on 9 adult conditions using the Penn Medicine Biobank (PMBB, n=48,279). We find a large number of patients - 50.1% (n=24,185) - were deemed by GIRA as high-risk for at least one of the 9 conditions with 30.4% (n=14,676) due to polygenic and/or monogenic risk. Stratifying by ancestry revealed significant differences in high-risk proportions, with higher rates in African/African American (AFR) (56.6% vs. 50.1%, p=7.43x10-36) and lower rates in East (42.0%) and South Asian (40.0%). Increased high-risk rates were observed in the lowest quartile of social deprivation index, highlighting the influence of environmental factors and access to care on GIRA's utility. GIRA was a good predictor of prevalent cases (in-line with the eMERGE GIRA reported results); incident case prediction was substantially attenuated for 5 of the 9 conditions (e.g., OR of 2.36 vs. HR of 1.31 for atrial fibrillation (AFIB)). We find demographic compositions of high-risk patients differed from the incident cases for some of the conditions; for example, high-risk for AFIB individuals where enriched for European ancestries in contrast with incident AFIB cases that were enriched for AFR ancestries. Overall, our results show the accuracy of GIRA as a biomarker to stratify high-risk patients for precision medicine and highlight implementation challenges in its impact on the health system if implemented at scale.
Year:
2026
We built and evaluated a zero-shot LLM pipeline with automated, task-aware prompt optimization to extract radiology and symptom fields for gallstone phenotyping from de-identified EHR text. Across symptomatic, asymptomatic, and control cohorts, it performed reliably on high-signal binary fields and symptom flags but lagged on fine-grained stone burden and complications, establishing a practical baseline and motivating targeted refinements
Year:
2026
Year:
2025
Aims The distribution of abdominal adipose depots and their mechanistic links to type 2 diabetes remain incompletely understood. This study elucidated the relationship between type 2 diabetes presence and quantitative abdominal imaging traits, including hepatic steatosis, liver and spleen size, and adipose distribution, using unenhanced computed tomography (CT) scans from a large-scale, racially diverse, disease-focused medical biobank. Materials and Methods Deep learning algorithms were applied to abdominal CT scans to automatically quantify image-derived phenotypes, including spleen-hepatic attenuation difference (SHAD) for hepatic steatosis, liver and spleen volumes (LV and SV, respectively), visceral and subcutaneous adipose tissue (VAT and SAT, respectively), and visceral-to-subcutaneous fat ratio (VSR). Results Diabetic individuals demonstrated a greater degree of hepatic steatosis and central adiposity than those without diabetes. Liver attenuation was lower (47.6 vs. 52.4 Hounsfield units (HU); lower values indicate greater steatosis), SHAD was higher (−5.41 vs. −8.41 HU; more positive values indicate greater steatosis), and steatosis prevalence increased (38.4% vs. 21.4%) (all p<2.2×10⁻¹⁶). VSR was also elevated (0.64 vs. 0.54, p=5.86×10⁻¹³). These trends remained significant after stratification by sex. Multivariate analyses revealed independent associations of diabetes with SHAD (OR 1.04), LV (OR 1.59), SV (OR 3.95), VAT (OR 1.23), SAT (OR 1.05), and VSR (OR 2.27), after adjusting for age, sex, race, and BMI. Conclusions Hepatic steatosis, hepatomegaly, and visceral adiposity on CT imaging are predictive of type 2 diabetes presence. Notably, VSR showed a stronger association with diabetes than BMI, underscoring how body-fat distribution, rather than overall adiposity, more accurately reflects metabolic disease risk.
Year:
2025
Genome-wide association studies (GWAS) have identified nearly 100 loci associated with metabolic dysfunction-associated steatotic liver disease (MASLD), but the molecular functions of these variant alleles remain elusive, particularly when they occur in non-coding regions. Here we profiled the chromatin accessibility landscape of liver nuclei from MASLD individuals, and demonstrated these accessible genomic sites were bound by cell type-specific transcription factors (TFs) and enriched for MASLD risk variants, highlighting lineage- and disease state-specific regulation. Using a massively parallel reporter assay (MPRA), we identified hundreds of differential activity variants (DAVs) that operate in a cell type-specific manner or in a stimulus-dependent context by disrupting liver pathogenesis-associated transcriptional regulatory network. Integrative analyses combining liver eQTLs, chromatin looping, and single-cell CRISPRi screening linked these DAVs to functional target genes. Notably, we demonstrated that DAVs located near SLC22A3 and core regulators of triglyceride metabolism ( APOA5 , ANGPTL3 , and LPL ) loci modulate their gene expression and contribute to altered lipid metabolism and hepatic stellate cell activation. Furthermore, these DAVs exhibit predictive power in distinguishing MASLD disease risk. Together, these multimodal integration analyses provide insights into the regulatory mechanisms of MASLD progression driven by noncoding genetic risks.
Year:
2025
Genome-wide association studies (GWAS) have identified thousands of loci associated with a variety of common, complex human traits. Recent efforts have focused on characterizing chromatin accessibility to discover regulatory elements that modify the expression of nearby genes, suggesting that trait associations are mediated through changes in gene regulation. Genetic variants associated with differences in chromatin accessibility, known as chromatin accessibility quantitative trait loci (caQTLs), are established contributors to gene expression differences, providing mechanistic hypotheses for signals identified by GWAS. Using the assay for transposase-accessible chromatin with sequencing (ATAC-seq), we assessed chromatin accessibility in 189 diverse human liver samples, identifying over two million accessible chromatin regions enriched for gene regulatory features and, in 175 of these samples, over 14,000 caQTLs. Focusing subsequently on liver-relevant complex traits, we obtained publicly available blood lipids GWAS data and identified 157 loci where caQTLs, expression quantitative trait loci (eQTLs), and GWAS signals colocalized. This generated specific molecular hypotheses about regulatory elements, affected genes, and, in some cases, implicated transcription factors. Finally, we enumerated the set of blood lipid trait signals that lack an obvious proposed mechanism beyond catalogs of liver caQTLs and eQTLs. After integrating 10 multi-omic QTL regulatory mechanism datasets whilst considering limitations in statistical power, we found that approximately 20% of blood lipid GWAS signals lacked a statistical link to a proposed mechanism. Our results demonstrate the value of integrating multiple genomic datasets to improve understanding of GWAS signals, while emphasizing the need for additional experimental approaches to fully characterize complex trait associations.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Collaborators (23)
Walter R. Witschey
Associate Professor
University of Pennsylvania
James Gee
Professor
University of Pennsylvania
Struan Grant
Professor of Genetics and Pediatrics
University of Pennsylvania
Sarah Abramowitz
Stanford University
Xiao Wang
University of Pennsylvania
Scott M Damrauer
Assistant Professor
University of Pennsylvania Perelman School of Medicine
Sy Hwang
University of Pennsylvania
Mitchell A Lazar
University of Pennsylvania
Kei Sakamoto
Professor at University of Copenhagen
University of Copenhagen
Danielle Mowery
Assistant Professor
University of Pennsylvania
Marijana Vujkovic
Research Assistant Professor
University of Pennsylvania
Benjamin F. Voight
Professor
University of Pennsylvania
Michael Levin
Cardiologist
Corporal Michael J. Crescenz VA Medical Center
Kate Townsend Creasy
Assistant Professor
University of Pennsylvania
Wenli Yang
Research Assistant Professor
University of Pennsylvania
Rinad S. Beidas
University of Pennsylvania
Kiran Musunuru
Professor
University of Pennsylvania
Hersh Sagreiya
Assistant Professor
University of Pennsylvania
Daniel P Kelly
Director
University of Pennsylvania
Won Dong Lee
Assistant Professor
Yonsei University
Kyong-Mi Chang
Professor of Medicine & Associate Chief of Staff for R&D
University of Pennsylvania
Dipsikha Biswas
Københavns Universitet
David Kaplan
Associate Professor, Clinician-Educator
University of Pennsylvania
Make your next move.
Prepare your application
Review drafts before you send them.